» Articles » PMID: 37724164

Fibroblast Growth Factor 21 and Dietary Interventions: What We Know and What We Need to Know Next

Overview
Journal Med Rev (2021)
Publisher De Gruyter
Specialty General Medicine
Date 2023 Sep 19
PMID 37724164
Authors
Affiliations
Soon will be listed here.
Abstract

Dietary interventions include the change of dietary styles, such as fasting and dietary or nutrient restrictions; or the addition of plant-derived compounds (such as polyphenols known as curcumin, resveratrol, or anthocyanin, or other nutraceuticals) into the diet. During the past a few decades, large number of studies have demonstrated therapeutic activities of these dietary interventions on metabolic and other diseases in human subjects or various animal models. Mechanisms underlying those versatile therapeutic activities, however, remain largely unclear. Interestingly, recent studies have shown that fibroblast growth factor 21 (FGF21), a liver-derived hormone or hepatokine, mediates metabolic beneficial effects of certain dietary polyphenols as well as protein restriction. Here I have briefly summarized functions of FGF21, highlighted related dietary interventions, and presented literature discussions on role of FGF21 in mediating function of dietary polyphenol intervention and protein restriction. This is followed by presenting my perspective view, with the involvement of gut microbiota. It is anticipated that further breakthroughs in this field in the near future will facilitate conceptual merge of classical medicine and modern medicine.

Citing Articles

Hepatic fibroblast growth factor 21 is required for curcumin or resveratrol in exerting their metabolic beneficial effect in male mice.

Feng J, Shao W, Yang L, Pang J, Ling W, Liu D Nutr Diabetes. 2025; 15(1):4.

PMID: 39929809 PMC: 11811165. DOI: 10.1038/s41387-025-00363-0.


The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review.

Negroiu C, Tudorascu R, Bezna M, Ungureanu A, Hontaru S, Danoiu S Rom J Morphol Embryol. 2024; 65(2):159-172.

PMID: 39020530 PMC: 11384831. DOI: 10.47162/RJME.65.2.02.

References
1.
Nonogaki K, Hazama M, Satoh N . Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy mice. Biomed Res Int. 2014; 2014:751930. PMC: 3997887. DOI: 10.1155/2014/751930. View

2.
Fon Tacer K, L Bookout A, Ding X, Kurosu H, John G, Wang L . Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010; 24(10):2050-64. PMC: 2954642. DOI: 10.1210/me.2010-0142. View

3.
Solon-Biet S, Cogger V, Pulpitel T, Wahl D, Clark X, Bagley E . Branched chain amino acids impact health and lifespan indirectly via amino acid balance and appetite control. Nat Metab. 2019; 1(5):532-545. PMC: 6814438. DOI: 10.1038/s42255-019-0059-2. View

4.
Liu D, Pang J, Shao W, Gu J, Zeng Y, He H . Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. Hepatology. 2021; 74(4):2154-2169. DOI: 10.1002/hep.31856. View

5.
Shao W, Jin T . Hepatic hormone FGF21 and its analogues in clinical trials. Chronic Dis Transl Med. 2022; 8(1):19-25. PMC: 9126297. DOI: 10.1016/j.cdtm.2021.08.005. View